Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased CXCL10 (IP-10) is associated with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse models.
Belmonte M, Cabrera-Cosme L, Øbro NF, Li J, Grinfeld J, Milek J, Bennett E, Irvine M, Shepherd MS, Cull AH, Boyd G, Riedel LM, Chi Che JL, Oedekoven CA, Baxter EJ, Green AR, Barlow JL, Kent DG. Belmonte M, et al. Among authors: baxter ej. Exp Hematol. 2024 Jul;135:104246. doi: 10.1016/j.exphem.2024.104246. Epub 2024 May 17. Exp Hematol. 2024. PMID: 38763471 Free article.
Iron homeostasis governs erythroid phenotype in polycythemia vera.
Bennett C, Jackson VE, Pettikiriarachchi A, Hayman T, Schaeper U, Moir-Meyer G, Fielding K, Ataide R, Clucas D, Baldi A, Garnham AL, Li-Wai-Suen CSN, Loughran SJ, Baxter EJ, Green AR, Alexander WS, Bahlo M, Burbury K, Ng AP, Pasricha SR. Bennett C, et al. Among authors: baxter ej. Blood. 2023 Jun 29;141(26):3199-3214. doi: 10.1182/blood.2022016779. Blood. 2023. PMID: 36928379 Free PMC article.
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
Grockowiak E, Korn C, Rak J, Lysenko V, Hallou A, Panvini FM, Williams M, Fielding C, Fang Z, Khatib-Massalha E, García-García A, Li J, Khorshed RA, González-Antón S, Baxter EJ, Kusumbe A, Wilkins BS, Green A, Simons BD, Harrison CN, Green AR, Lo Celso C, Theocharides APA, Méndez-Ferrer S. Grockowiak E, et al. Among authors: baxter ej. Nat Cancer. 2023 Aug;4(8):1193-1209. doi: 10.1038/s43018-023-00607-x. Epub 2023 Aug 7. Nat Cancer. 2023. PMID: 37550517 Free PMC article.
Convergent somatic evolution commences in utero in a germline ribosomopathy.
Machado HE, Øbro NF, Williams N, Tan S, Boukerrou AZ, Davies M, Belmonte M, Mitchell E, Baxter EJ, Mende N, Clay A, Ancliff P, Köglmeier J, Killick SB, Kulasekararaj A, Meyer S, Laurenti E, Campbell PJ, Kent DG, Nangalia J, Warren AJ. Machado HE, et al. Among authors: baxter ej. Nat Commun. 2023 Aug 22;14(1):5092. doi: 10.1038/s41467-023-40896-5. Nat Commun. 2023. PMID: 37608017 Free PMC article.
Inherited polygenic effects on common hematological traits influence clonal selection on JAK2V617F and the development of myeloproliferative neoplasms.
Guo J, Walter K, Quiros PM, Gu M, Baxter EJ, Danesh J, Di Angelantonio E, Roberts D, Guglielmelli P, Harrison CN, Godfrey AL, Green AR, Vassiliou GS, Vuckovic D, Nangalia J, Soranzo N. Guo J, et al. Among authors: baxter ej. Nat Genet. 2024 Feb;56(2):273-280. doi: 10.1038/s41588-023-01638-x. Epub 2024 Jan 17. Nat Genet. 2024. PMID: 38233595 Free PMC article.
Maintenance of hematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition.
Williams MJ, Wang X, Bastos HP, Grondys-Kotarba G, Wu Q, Jin S, Johnson CS, Mende N, Calderbank EF, Wantoch M, Park HJ, Mantica G, Hannah RL, Wilson NK, Pask DC, Hamilton TL, Kinston SJ, Asby R, Sneade R, Baxter EJ, Campbell PJ, Vassiliou GS, Laurenti E PhD, Li J, Gottgens B, Green AR. Williams MJ, et al. Among authors: baxter ej. Blood Adv. 2024 Oct 7:bloodadvances.2024014046. doi: 10.1182/bloodadvances.2024014046. Online ahead of print. Blood Adv. 2024. PMID: 39374575 Free PMC article.
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis.
Fang Z, Corbizi Fattori G, McKerrell T, Boucher RH, Jackson A, Fletcher RS, Forte D, Martin JE, Fox S, Roberts J, Glover R, Harris E, Bridges HR, Grassi L, Rodriguez-Meira A, Mead AJ, Knapper S, Ewing J, Butt NM, Jain M, Francis S, Clark FJ, Coppell J, McMullin MF, Wadelin F, Narayanan S, Milojkovic D, Drummond MW, Sekhar M, ElDaly H, Hirst J, Paramor M, Baxter EJ, Godfrey AL, Harrison CN, Méndez-Ferrer S. Fang Z, et al. Among authors: baxter ej. Nat Commun. 2023 Nov 25;14(1):7725. doi: 10.1038/s41467-023-43175-5. Nat Commun. 2023. PMID: 38001082 Free PMC article. Clinical Trial.
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, Fox S, Ailts I, Dueck AC, Geyer HL, Mesa RA, Dunn WG, Nadezhdin E, Curto-Garcia N, Green A, Wilkins B, Coppell J, Laurie J, Garg M, Ewing J, Knapper S, Crowe J, Chen F, Koutsavlis I, Godfrey A, Arami S, Drummond M, Byrne J, Clark F, Mead-Harvey C, Baxter EJ, McMullin MF, Mead AJ. Harrison CN, et al. Among authors: baxter ej. J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1. J Clin Oncol. 2023. PMID: 37126762 Free PMC article. Clinical Trial.
Life histories of myeloproliferative neoplasms inferred from phylogenies.
Williams N, Lee J, Mitchell E, Moore L, Baxter EJ, Hewinson J, Dawson KJ, Menzies A, Godfrey AL, Green AR, Campbell PJ, Nangalia J. Williams N, et al. Among authors: baxter ej. Nature. 2022 Feb;602(7895):162-168. doi: 10.1038/s41586-021-04312-6. Epub 2022 Jan 20. Nature. 2022. PMID: 35058638
45 results